Genascence

Executive Summary

Genascence is a clinical-stage biotechnology company developing gene therapies for musculoskeletal diseases, with a primary focus on osteoarthritis (OA). Its lead candidate, GNSC-001, is a one-time, intra-articular gene therapy designed to block the inflammatory cytokine IL-1, aiming to provide long-term pain relief and slow joint degeneration. Founded in 2020 and based in Gainesville, Florida, the company addresses a significant unmet need in OA, a highly prevalent condition with limited disease-modifying treatments. GNSC-001 has the potential to transform OA management by offering a durable therapeutic effect from a single injection, reducing the burden of repeated treatments and improving patient outcomes.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 Clinical Trial Initiation or First Patient Dosed80% success
• Q4 2026Initial Safety and Biomarker Data from Phase 1 Trial60% success
• TBDPartnership or Licensing Deal for GNSC-00130% success